Brian McVeigh, Code Bio CEO
Takeda signs off on a $2B deal aimed at bypassing AAV roadblocks on the way to gene therapy 2.0
Takeda has taken another step down the road to building up its gene therapy platform.
The pharma giant announced Tuesday morning that it’s struck the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
